GBC’s CellBio™ liquid biopsy platform has earned a Bronze Award in the Medical Device category at the National Pharmaceutical Technology & R&D Awards, a prestigious national program co-hosted by the Taiwan Food and Drug Administration (TFDA) and the Industrial Development Administration, MOEA. The award recognizes outstanding innovation, clinical potential, and industry impact.

iFiltration™ Technology: Enabling Intact CTC Capture

CellBio™ uses patented iFiltration™ technology to automatically capture and preserve intact circulating tumor cells (CTCs) and other rare cells directly from blood samples.
This preserves cell morphology and protein expression, enabling downstream cytology, immunostaining, FISH, qPCR, NGS, and other multi-omic analyses, supporting precision oncology workflows.

Driving the Future of Precision Medicine

CellBio™ bridges research and clinical practice, empowering physicians with actionable insights for early detection, disease monitoring, and treatment evaluation.
This recognition reflects GBC’s leadership in automated intact-cell analysis and reinforces our commitment to innovation in translational medicine.

Looking Ahead

With an integrated ecosystem spanning R&D, manufacturing, clinical applications, and laboratory services, GBC is advancing CellBio™ solutions worldwide to make precision diagnostics more accessible and impactful.